ArticleFrontiers in nutrition2025
Dietary soy and isoflavone intake and mortality in Korean adults: a prospective cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between dietary soy and isoflavone intake and mortality remains inconclusive. This study aimed to examine the relationships of dietary intakes of isoflavones, soy protein, and soy foods with all-cause, cancer, and cardiovascular disease (CVD) mortality in Korean adults. Methods: This prospective cohort study included 118,450 Korean adults aged 40-79 years from the Health Examinees Study (2004-2013). Dietary intakes of isoflavones, soy protein, and soy foods were assessed using a food frequency questionnaire. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality risk according to quartiles of dietary soy and isoflavone intake. Results: During a median follow-up of 10.1 years (interquartile range: 8.7-11.4 years), 2,614 deaths were documented, including 1,290 from cancer and 389 from CVD. Multivariable analyses showed no significant associations between dietary isoflavone intake and the risk of all-cause and cause-specific mortality. The HRs (95% CIs) comparing the highest vs. the lowest quartile of isoflavone intake were 1.04 (0.93-1.15) for all-cause mortality, 0.98 (0.84-1.14) for cancer mortality, and 1.04 (0.79-1.38) for CVD mortality. Similarly, no significant associations were observed for soy protein or soy food intake in relation to all-cause, cancer, and CVD mortality. Conclusion: Our study found no significant associations of dietary intakes of isoflavones, soy protein, and soy foods with the risks of all-cause, cancer, and CVD mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.